Myeloproliferative neoplasm
MONDO:0020076A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Also known as: CMPD, MPD, MPN, chronic myeloproliferative disease, chronic myeloproliferative disorder, chronic myeloproliferative neoplasm, myeloproliferative disorder, myeloproliferative neoplasm
4617 clinical trials for this condition and its sub-types, 166 tagged with Myeloproliferative neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myeloproliferative neoplasm
-
Myeloid leukemia 30 trials · 1,334 incl. sub-types
4 sub-types
- Acute myeloid leukemia 1,098 trials · 1,194 incl. sub-types Sub-types →
- Chronic myelogenous leukemia, BCR-ABL1 positive 211 trials · 253 incl. sub-types Sub-types →
- Atypical chronic myeloid leukemia, BCR-ABL1 negative 17 trials
- Philadelphia-positive myelogenous leukemia 2 trials
-
Myelodysplastic/myeloproliferative neoplasm 81 trials · 234 incl. sub-types
2 sub-types
- Chronic myelomonocytic leukemia 167 trials · 187 incl. sub-types Sub-types →
- Atypical chronic myeloid leukemia, BCR-ABL1 negative 17 trials
-
Primary myelofibrosis 191 trials · 195 incl. sub-types
4 sub-types
- Cellular phase chronic idiopathic myelofibrosis 16 trials
- Myelofibrosis with myeloid metaplasia 1 trial
- Familial myelofibrosis 0 trials
- Panostotic fibrous dysplasia 0 trials
-
Myelofibrosis 149 trials
-
Erythroid neoplasm 0 trials · 95 incl. sub-types
2 sub-types
- Acquired polycythemia vera 90 trials
- Acute erythroid leukemia 5 trials Sub-types →
-
Essential thrombocythemia 67 trials
-
Therapy-related myeloid neoplasm 54 trials
-
Myeloproliferative neoplasm, unclassifiable 11 trials · 16 incl. sub-types
1 sub-type
-
Transient myeloproliferative syndrome 13 trials
-
Chronic neutrophilic leukemia 10 trials
-
Chronic eosinophilic leukemia 9 trials
-
Thrombocytopenia 6 0 trials
Most studied deeper sub-types
-
Promising combo for IDH1 leukemia hits early snag – trial stopped
Disease control Stopped earlyThis early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…
Phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug tested for Post-Transplant blood cancers — but study halted early
Disease control Stopped earlyThis pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…
Phase 2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stem cell transplant study halted early: which prep works best?
Disease control Stopped earlyThis study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…
Phase 3 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Blood cancer drug fails to show promise in Post-Transplant trial
Disease control Stopped earlyThis early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose a…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for blood cancer patients: drug shows promise in controlling disease
Disease control Stopped earlyThis study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…
Phase 2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Blood pressure drug tested to prevent transplant complication
Prevention Stopped earlyThis pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…
Sponsor: Hackensack Meridian Health • Aim: Prevention
Last updated Jun 27, 2026 12:03 UTC
-
Liver study for cancer drug stopped early – only 2 people joined
Knowledge-focused Stopped earlyThis study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC